Know more

Simon completed postgraduate work at the Medical Research Council’s Clinical Research Centre then postdoctoral work at New York University School of Medicine and Yale University prior to  a faculty position at the University of Pennsylvania, Philadelphia and the development of a research programme focusing on gut biology and immunology. Returned to the UK and the University of Leeds to develop a new programme of research focusing on commensal gut bacteria leading to the development of a Bacteroides drug delivery technology platform for the development of new treatments for GI-related diseases. Relocated to the Quadram Institute and Univ. East Anglia to develop and lead a multidisciplinary Gut Biology Research Programme. A current focus is using commensal gut bacteria derived microvesicles for boosting natural immunity in at risk individuals, and for the delivery of therapeutic proteins and vaccine antigens to mucosal sites to treat or prevent autoimmne- or infection-related diseases that target the GI-tract and the brain (the gut-brain axis).